By A. Kaelin. University of Newport. 2018.
But once the project workers who have good participatory and tech- planning phase is over discount propecia 1mg free shipping, monitoring should go along nical skills so that he can engage after the per- the pre-defined objectives cheap 1mg propecia otc, targets and activity formance in a dialogue with the audience. Task 6: Developing a project budget Task 4: Defining aims and objectives How project budget are done and how flexible This task is closely connected to the first task. Often Everybody will agree that getting aims and objec- budgeting is a ‘reality check’ and objectives and tives clear is essential, but smaller initiatives often targets need to be revisited after the budgeting do not give enough care to this step. Developing a project budget demands 474 Gynecological Care and the Health System Table 1 An example of a chronogram or Ghantt chart Task 8: Getting the approval for the project plan for cervical cancer screening promotion program Finally, the project planning document needs the Activity/months Jan Feb March April May approval from the funding organization and key stakeholders. If the project involves research a re- Assessment of needs X search permit for the respective research activity and stakeholder might also be needed. The funding organization meeting will look in particular into the aims and objectives Training of drama X as well as the overall coherence, in particular group whether timelines or budgets are realistic. Piloting in 2 villages X CONCLUSION AND REMARKS Stakeholder meeting X and adaptation of This chapter was written with a view to sensitizing approach healthcare providers delivering care in gynecology Conducting drama X X at the district hospital on a few important health group sessions in 8 system aspects. Health providers often overlook the villages complexity of health systems. Aspects of referral to higher level and cooperation with the community are important for prevention and care. Careful consideration of integration and linkages of services much experience and knowledge of local context can improve use of services and client satisfaction such as who gets which kind of remuneration, with services offered. The first task in Delivering care is not enough; clients in need budgeting is commonly to (1) divide activities into must also be reached. Health promotion is essential as many sub-activities as needed for budgeting, (2) for achieving the goal of better health for women get sufficient information on remuneration, allow- – prevention is essential, care and treatment alone ances schemes and transport costs as possible and (3) will not reach best levels of health. It is best to do the calculations in Excel to avoid mistakes, but should be accompanied by a narrative INTERESTING WEBSITES AND FURTHER description. Budget summaries per major activity READING and per year are helpful for financial planning. It is not difficult to imagine how Linkages and synergies important it is that cervical cancer screening is con- The WHO homepage has several documents for tinuously offered to ensure credibility of the health further reading on synergies and linkages, particu- promotion project. A risk might be for ductivehealth/publications/linkages/en/ example that key project staff leave the project. Good project planning respects risks and puts Health promotion mechanism in place to mitigate them, for example always training two staff members on the same MacDowall W, Bonell C, Davies M, eds. Health activity so that they can replace each other. Too far to walk: maternal mor- Maidenhead, UK: Open University Press, 2006 tality in context. Still too far to walk: literature WHO homepage on health promotion: http:// review of the determinants of delivery service use. Overcoming barriers to health German Health Practice Collection. Best practise service access: influencing the demand side. Health Policy homepage gives several examples of health promo- Plan 2004;19:69–79 9. Declaration of tion projects from various countries, mostly in the Alma-Ata. International Conference on Primary Health Care, field of HIV prevention and reproductive health: Alma-Ata, USSR, 6–12 September 1978. Integrating Maternal and The Breast Health Global Initiatives to promote Child Health Services with Primary Health Care. Everybody’s business: the gap in a generation: health equity through action on the strengthening health systems to improve health outcomes: social determinants of health. Milestone in Health Promo- Health Systems to Make Them Stronger. Health Promo- tation, District Health Systems for Primary Health Care. Tools for Open University Press, 2006 monitoring the effectiveness of district maternity referral systems.
Reported infections include: • Active tuberculosis purchase propecia 1mg without a prescription, including reactivation of latent tuberculosis purchase 1 mg propecia with visa. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before CIMZIA use and during therapy. Treatment for latent infection should be initiated prior to CIMZIA use. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients. Similar boxed warnings have been issued on Simponi (Golimumab). WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES SERIOUS INFECTIONS Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel Enbrel should be discontinued if a patient develops a serious infection or sepsis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe Targeted immune modulators 175 of 195 Final Update 3 Report Drug Effectiveness Review Project Trade names (active ingredients) Boxed warnings, warnings and precautions systemic illness. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. WARNING: PROGRESSIV MUTIFOCAL LEUKOENCEPHAOPATHY TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI as monotherapy. Under the TOUCH™ Tysabri Prescribing Program, only prescribers, infusion centers, and pharmacies associated (natalizumab) with infusion centers registered with the program are able to prescribe, distribute, or infuse the product. In addition, TYSABRI must be administered only to patients who are enrolled in and meet all the conditions of the TOUCH™ Prescribing Program.
It is thought to result in redistribution of autoaggressive lymphocytes (T cells and B cells) to the lymph nodes and away from the central nervous system cheap propecia 5 mg mastercard. The purpose of this addendum to the larger report on drugs to treat multiple sclerosis is to review the evidence on the comparative effectiveness and harms of fingolimod compared to the 2 other 5 drugs previously reviewed purchase propecia 5mg on line. Placebo-controlled evidence will be used only where comparative data are not available. A glossary of terms used in Drug Effectiveness Review Project Reports is included in the main report on disease-modifying drugs for multiple sclerosis. Included drugs Dosage and Agent administration Indication Mechanism of action Patients with relapsing forms of A sphingosine 1-phosphate receptor multiple sclerosis to reduce the modulator and is reported to work at Fingolimod 0. Effective in periphery into the CNS by PS once weekly patients who experienced first decreasing the production of clinical episode and have MRI adhesion molecules and increasing features consistent with MS the production of metalloproteases Treatment of relapsing forms of on the vascular endothelium that 22 or 44 mcg MS to decrease the frequency of constitutes the blood brain barrier. Interferon beta-1a Subcutaneously ® clinical exacerbations and delay These agents may also inhibit the Rebif three times the accumulation of physical generation of pro-inflammatory weekly disability cytokines from Th1 cells (TNFα, Treatment of relapsing forms of IFNγ, IL-12). Effective in Every other day patients who experienced first MS drugs addendum: fingolimod 6 of 32 Final Original Report Drug Effectiveness Review Project Dosage and Agent administration Indication Mechanism of action clinical episode and have MRI features consistent with MS Treatment of relapsing forms of MS to reduce frequency of clinical 0. Effective in ® Subcutaneously Extavia patients who experienced a first every other day clinical episode and have MRI features consistent with MS Inhibits cell division and impairs the 2 proliferation of T cells, B cells and 12 mg/m macrophages by intercalating and Intravenously Reduce neurologic disability crosslinking DNA, thus inhibiting Mitoxantrone Every 3 months and/or the frequency of clinical ®b DNA replication and RNA synthesis Novantrone (Maximum relapses in SPMS, PRMS or of these cells. Impairs antigen cumulative dose worsening RRMS 2 presentation by causing apoptosis of is 140 mg/m ) APCs and other cells that associate with APCs. Binds to α4 integrins expressed on Treatment of relapsing forms of leukocytes, which prevents binding 300 mg multiple sclerosis to delay the to adhesion cells VCAM-1 and Natalizumab ®c Intravenously accumulation of physical disability MAdCAM-1 on the vascular Tysabri every 4 weeks and reduce frequency of clinical endothelium and prevents migration exacerbations of leukocytes from the periphery into the CNS. Abbreviations: APC, antigen-presenting cell; CIS, clinically isolated syndrome; CNS, central nervous system; DNA, deoxyribonucleic acid; IL, interleukin; MAdCAM-1, mucosal vascular addressin cell adhesion molecule-1; MBP, myelin basic protein; MHC, major histocompatibility complex; MRI, magnetic resonance imaging; MS, multiple sclerosis; RNA, ribonucleic acid; PRMS, progressive relapsing multiple sclerosis; PS, prefilled syringes; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; TCR, T cell receptor; Th, T- helper; TNF, Tumor Necrosis Factor; VCAM-1, vascular cell adhesion molecule-1. Scope and Key Questions The goal of this report is to compare the effectiveness and adverse event profile of fingolimod to the other disease-modifying drugs in the treatment of multiple sclerosis. The key questions for this addendum are based on those in the complete report. There may be questions below that are not relevant to this addendum; these are noted by brackets [ ]. A draft of these questions and inclusion and exclusion criteria were posted on the Drug Effectiveness Review Project website. The draft was reviewed and revised by representatives of the organizations participating in the Drug Effectiveness Review Project. Revision took into consideration input from the public and the organizations’ desire for the key questions to reflect populations, drugs, and outcome measures of interest to clinicians and patients. These organizations approved the following key questions to guide the review for this report: MS drugs addendum: fingolimod 7 of 32 Final Original Report Drug Effectiveness Review Project Key Questions 1. What is the comparative effectiveness of fingolimod and other disease-modifying treatments for multiple sclerosis, including use of differing routes and schedules of administration? What is the effectiveness of fingolimod and other disease-modifying treatments for patients with a clinically isolated syndrome? Do fingolimod and other disease-modifying treatments for multiple sclerosis differ in harms? Are there subgroups of patients based on demographics (age, racial or ethnic groups, and gender), socioeconomic status, other medications, severity of disease, or co-morbidities for which fingolimod is more effective or associated with fewer adverse events than other disease-modifying treatment? METHODS Inclusion Criteria Population(s) 3, 4 • Adult outpatients with multiple sclerosis o Primary progressive multiple sclerosis o Secondary progressive multiple sclerosis o Relapsing-remitting multiple sclerosis o Progressive relapsing multiple sclerosis • Adult outpatients with a clinically isolated syndrome (also known as “first demyelinating event”, first clinical attack suggestive of multiple sclerosis, or 3 monosymptomatic presentation). Intervention Generic Name Trade Name Form Fingolimod Gilenya™ Capsule MS drugs addendum: fingolimod 8 of 32 Final Original Report Drug Effectiveness Review Project Comparators Generic name Trade name(s) Form(s) ® Glatiramer acetate Copaxone Injectable ® Avonex Vial Interferon beta-1a ® Rebif Syringe ® Betaseron Vial Interferon beta-1b ®a Extavia Injectable ® Mitoxantrone Novantrone Injectable ® Natalizumab Tysabri Vial Placebo a Not available in Canada. Effectiveness Outcomes Multiple sclerosis Clinically isolated syndrome • Disability • Disability • Clinical exacerbation/relapse • Clinical exacerbation/relapse of • Quality of life symptoms • Functional outcomes (e. For effectiveness, controlled clinical trials and good-quality systematic reviews. Observational studies with 2 concurrent arms of at least 100 patients each and duration ≥1 year are included (e. For harms, in addition to controlled clinical trials, observational studies are included. Literature Search ® ® We searched Ovid MEDLINE (1996-week 4 December 2010), Ovid MEDLINE In-Process & Other Non-Indexed Citations (November 08, 2010), the Cochrane Database of Systematic ® ® Reviews (4th Quarter, 2010), the Cochrane Central Register of Controlled Trials (4th Quarter, 2010), and Database of Abstracts of Reviews of Effects (DARE) using included drugs, MS drugs addendum: fingolimod 9 of 32 Final Original Report Drug Effectiveness Review Project indications, and study designs as search terms (see Appendix A for complete search strategies).
Results from this 33 systematic review and meta-analysis are summarized below cheap propecia 1mg online. Twenty-five studies which included randomized trials purchase propecia 1 mg without a prescription, abstracts, and non-English publications were included in the systematic review and meta-analysis by Ashcroft, et al. Of these, 11 trials assessed pimecrolimus 1% cream (8 vehicle-controlled, 2 active-control, 1 head- to-head) and 14 trials assessed tacrolimus 0. The primary outcome was a combination of 2 similar endpoints: 1) the proportion of patients with clear or almost clear resolution of disease as assessed by investigators per IGA score ≤1 for pimecrolimus trials and 2) the proportion of patients who achieved at least a 90% improvement in their lesions from baseline per PGE 90% to 100% for tacrolimus trials. Ashcroft and colleagues refer to the combined outcome as “investigators’ global assessment of response. Adjusted indirect meta-analyses comparing tacrolimus ointment with pimecrolimus cream was not performed but analyses comparing tacrolimus or pimecrolimus with vehicle were conducted. Active-control trials with topical steroids as the comparator were grouped by the relative topical steroid potency. Table 4 provides a summary of the results for the primary outcome. Compared with vehicle, treatment with tacrolimus (0. One head-to-head study, however, found no significant difference between tacrolimus 0. Compared with relatively more potent topical steroids (betamethasone valerate, hydrocortisone butyrate), tacrolimus 0. Topical calcineurin inhibitors Page 19 of 74 Final Report Drug Effectiveness Review Project a Table 4. Summary of results for “investigators’ global assessment of response” from a meta-analysis by Ashcroft, et al. Number of b included Relative risk studies (95% CI) At 3 weeks Pimecrolimus compared with vehicle 5 2. Abbreviations: BMV, betamethasone valerate; HB, hydrocortisone butyrate; HCA, hydrocortisone acetate. For adults and children with stable atopic dermatitis or eczema, do pimecrolimus or tacrolimus differ in effectiveness when compared to each other and when compared to topical corticosteroids depending on location of application (e. Summary Shorter-term treatment (≤12 weeks) Mild to moderate disease Tacrolimus 0. Improvements in pruritus were also not significantly different between tacrolimus 0. None of the studies that included mild to moderate disease severity reported patients’ assessment of overall disease control and none stratified efficacy outcomes depending on affected body surface area. Evidence evaluating treatment effect in the head/neck area was found but is limited. Only 1 tacrolimus trial and 1 pooled pimecrolimus study reported mean EASI score improvement which suggests that pimecrolimus 1% cream may be slightly more, or as effective as tacrolimus 0. We did not find any studies that investigated higher strength tacrolimus 0. Moderate to severe disease There is insufficient head-to-head evidence comparing lower strength tacrolimus 0. There was also little difference in pruritus score (pooled weighted mean difference 0. Direct and indirect evidence reported conflicting results when higher strength tacrolimus 0. In contrast, indirect comparison of 3 tacrolimus and 1 pimecrolimus trial revealed no statistically significant differences in treatment success (pooled relative risk 1. Results from indirect meta-analyses for both mild to moderate and moderate to severe disease should be considered with caution due to limited evidence and in some instances wide confidence intervals suggesting wider variability in the estimated point estimate. Quality of life There is insufficient evidence to assess whether one topical calcineurin inhibitor has “better” quality of life profile compared with another topical calcineurin inhibitor.
10 of 10 - Review by A. Kaelin
Votes: 314 votes
Total customer reviews: 314